ICI restores anti-tumor immunity by inhibiting the interaction between immune checkpoints such as programmed cell death protein-1 (PD-1) or cytotoxic T lymphocyte antigen-4 (CTLA-4) and their ligands. This evidence concerns the gene PDCD1 and neoplasm.